Nemtabrutinib
Small molecule
Also known as MK-1026
Evidence outlook · registrational
Chronic Lymphocytic Leukemia: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-05-19.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Chronic Lymphocytic Leukemia: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nemtabrutinib: this drug | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Acalabrutinib | Approved | Small molecule | BTK | Partial signal | Featured results are non-efficacy only in this race | |
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | not yet graded | No reviewed efficacy summary in this indication | |
| Ibrutinib | Approved | Small molecule | BTK | Partial signal | NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62) | |
| Obinutuzumab | Approved | Monoclonal antibody | CD20 | Partial signal | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Pirtobrutinib | Approved | Small molecule | BTK | Partial signal | Featured results are non-efficacy only in this race | |
| Rituximab (Rituxan) | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | not yet graded | No reviewed efficacy summary in this indication | |
| Rituximab-Abbs (Truxima) | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Venetoclax | Approved | Small molecule | BCL-2 | Partial signal | NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001) | |
| Zanubrutinib (Brukinsa) | Approved | Small molecule | BTK | Partial signal | NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results). | |
| Bexobrutideg | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded | No reviewed efficacy summary in this indication | |
| Sonrotoclax (Beqalzi) | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mesutoclax | Phase 2/3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| MS-553 | Phase 1/2 | Small molecule | Protein kinase C-beta (PKC-beta) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(17 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Nemtabrutinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.